Stelara 45 MG/0.5 ML syringe 0.5ML
Ended Awarded Last action
- Contract number
- SPE2DR26FT6BQ
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $19,320
Award facts
- Contract value 100% obligated
- $19,320.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $19,320.00 to AmerisourceBergen Drug Corp for the supply of Stelara 45 mg/0.5 ml syringes on January 29, 2026, with an ultimate completion date of January 30, 2026. This firm fixed-price delivery order is unset-aside and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The contract represents a task order under AmerisourceBergen's parent company Cencora, Inc.'s substantial Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 2031, which serves as the primary vehicle for delivering pharmaceutical products and medical supplies to support military healthcare programs globally.
AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor for federal medical procurement, was selected through open competition to fulfill this pharmaceutical delivery requirement. The company's extensive federal contracting history demonstrates its capability to supply a comprehensive range of brand-name and generic medications, vaccines, and medical supplies across multiple therapeutic domains to military treatment facilities, veteran healthcare programs, and other federal medical institutions. Stelara is a specialty immunosuppressant medication used to treat conditions such as plaque psoriasis, psoriatic arthritis, and Crohn's disease, reflecting the Defense Logistics Agency's ongoing commitment to maintaining adequate pharmaceutical inventories for military healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FT6BQ?
SPE2DR26FT6BQ was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 29, 2026.
How much is contract SPE2DR26FT6BQ worth?
The government has obligated $19,320 on SPE2DR26FT6BQ.
Is contract SPE2DR26FT6BQ an order under another contract?
Yes. SPE2DR26FT6BQ is a delivery order under SPE2DR25D3201, an indefinite delivery contract.
Was contract SPE2DR26FT6BQ competed?
The extent of competition for SPE2DR26FT6BQ was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award